Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy

Onkologie
Karin Jordan

Abstract

Aprepitant (Emend), the first neurokinin-1-receptor antagonist (NK-1-RA), represents a new class of antiemetics. Aprepitant has been approved for the prevention and treatment of acute (0-24 h after chemotherapy) and delayed (1-5 days after chemotherapy) emesis resulting from cisplatin-based chemotherapy and moderately emetogenic chemotherapy. The addition of aprepitant to standard antiemetic therapy in cisplatin-based chemotherapy significantly improves emesis protection in general and, in particular, in the delayed phase by approximately 20%. Results from a recently published study in patients receiving moderately emetogenic chemotherapy suggest a benefit of aprepitant when combined with dexamethasone and a 5-HT(3) receptor antagonist for the prevention of acute emesis, followed by aprepitant as a single agent in the prevention of delayed emesis. Altogether, the addition of aprepitant to the standard antiemetic regimen (5-HT(3) receptor antagonist and dexamethasone) significantly improves the protection against vomiting in the acute as well as in the delayed phase in highly and moderately emetogenic chemotherapies. Therefore, the combination of a 5-HT(3) receptor antagonist, dexamethasone and aprepitant should be considered as...Continue Reading

References

Feb 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M GriffinM H Tattersall
Jun 4, 1997·Journal of the National Cancer Institute·M G KrisP J Hesketh
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethS L Silberman
Oct 13, 2000·Drugs·P Diemunsch, L Grélot
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CamposB J Gertz
Apr 21, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V CocquytB J Gertz
Feb 28, 2002·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jørn Herrstedt
Feb 28, 2002·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fausto RoilaGuido Margutti
May 21, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Su-Er W HuskeyShuet-Hing L Chiu
Jul 5, 2003·Clinical Pharmacology and Therapeutics·Jacqueline B McCreaRobert A Blum
Nov 19, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fausto RoilaJorn Herrstedt
Nov 27, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jørn HerrstedtMario Dicato
Nov 27, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mark G KrisEnzo Ballatori
Jan 22, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karin JordanHans-Joachim Schmoll
Feb 22, 2005·Cancer Chemotherapy and Pharmacology·Peter NygrenSimon van Belle
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G WarrFranck Skobieranda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.